The diagnostic value of adrenomedullin and its relation with severity in patients with systolic heart failure

Aim: Adrenomedullin (ADM) is a vasodilator, natriuretic and antiproliferative peptide that lowers blood pressure and inhibits cellmigration. The expression of cardiac ADM is increased in heart failure (HF). The objective of this study was to investigate andsimultaneously compare the levels of probrain natriuretic peptide (pro-BNP) and ADM as a potential marker in patients with HF.Material and Methods: In this study, plasma levels of probrain natriuretic peptide and ADM were investigated in 90 subjects withsystolic heart failure and 90 healthy controls. The results were compared with appropriate statistical methods.Results: ADM levels were increased in patients with systolic HF with mean levels of 87.7 (81.4–99.7) pg/mL in HF group and 70.8(65.2–78.7) pg/mL in healthy controls (p < 0.001). Elevated ADM levels in HF were found to demonstrate a positive correlation withNew York Heart Association (NYHA) functional classifiation (r = 0.94, p < 0.001) and pulmonary arterial systolic pressure (PASP) (r =0.44, p

PDF

___

1. Nagaya N, Satoh T, Nishikimi T, et al. Hemodynamic, renal, and hormonal effects of adrenomedullin infusion in patients with congestive heart failure. Circulation 2000;101:498-503.
2. Sugo S, Minamino N, Kangawa K, et al. Endothelial cells actively synthesize and secrete adrenomedullin. Biochem Biophys Res Commun 1994;201:1160-6.
3. Ishiama Y, Kitamura K, Ichiki Y. Hemodynamic effects of a novel hypotensive peptide, human adrenomedullin, in rats. Eur J Pharmacol 1993;241:271-3.
4. Wong HK, Cheung TT, Cheung BM. Adrenomedullin and cardiovascular diseases. JRSM Cardiovasc Dis 2012;10:1-5.
5. Kitamura K, Sakata J, Kangawa K. Cloning and characterization of cDNA encoding a precursor for human adrenomedullin. Biochem Biophys Res Commun 1993;194:720-5.
6. Ishimitsu T, Kojima M, Kangawa K. Genomic structure of human adrenomedullin gene. Biochem Biophys Res Commun 1994;203:631-9.
7. McMurray JJ, Petrie MC, Murdoch DR, et al. Clinical epidemiology of heart failure: public and private health burden. Eur Heart J 1998;19:9-16.
8. Jourdain P, Funck F, Bellorini M, et al. Bedside B-type natriuretic peptide and functional capacity in chronic heart failure. Eur J Heart Fail 2003;5:155-60.
9. Koglin J, Pehlivanli S, Schwaiblmair M, et al. Role of brain natriuretic peptide in risk stratifiation of patients with congestive heart failure. J Am Coll Cardiol 2001;38:1934-41.
10. Swedberg K, Cleland J, Dargie H, et al. Task force for the diagnosis, treatment of chronic heart failure of the european society of cardiology. Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): The task force for the diagnosis and treatment of chronic heart failure of the european society of cardiology. Eur Heart J 2005; 26:1115-40.
11. Lang RM, Bierig M, Devereux RB, et al. Recommendations for chamber quantifiation: a report from the american society of echocardiography’s guidelines and standards committee and the chamber quantifiation writing group, developed in conjunction with the european association of echocardiography, a branch of the european society of cardiology. J Am Soc Echocardiogr 2005;18:1440-63.
12. Burkhardt H, Bojarsky G, Gretz N, et al. Creatinine clearance, cockcroft- gault formula and cystatin C: estimators of true glomerular fitration rate in the elderly? Gerontology 2002;48:140-6.
13. Kitamura K, Kangawa K, Kawamoto M. Adrenomedullin: A novel hypotensive peptide isolated from human pheochromocytoma. Biochem Biophys Res Commun 1993;192:553-60.
14. Kobayashi K, Kitamura K, Eto T. Increased plasma adrenomedullin levels in chronic congestive heart failure. Am Heart J 1996;131:994-8.
15. Kato J, Kobayashi K, Etoh T, et al. Plasma adrenomedullin concentration in patients with heart failure. J Clin Endocrinol Metab 1996;81:180-3.
16. Jougasaki M, Rodeheffer RJ, Redfild MM, et al. Cardiac secretion of adrenomedullin in human heart failure. J Clin Invest 1996;97:2370-6.
17. Kobayashi K, Kitamura K, Hirayama N, et al. Increased plasma adrenomedullin in acute myocardial infarction. Am Heart J 1996;131:676-80.
18. Sato K, Hirata Y, Imai T, et al. Characterization of immunoreactive adrenomedullin in human plasma and urine. Life Sci 1994;57:189-94.
19. Somma SD, Anand I, Ng L, et al. Mid-region prohormone markers for diagnosis and prognosis in acute dyspnea: results from the BACH trial. J Am Coll Cardiol 2010;55:2062-76.
20. Haehling S, Filippatos G, Papassotiriou J, et al. Midregional pro-adrenomedullin as a novel predictor of mortality in patients with chronic heart failure. Eur J Heart Fail 2010;12:484-91.
21. Morbach C, Marx A, Kaspar M, et al. Prognostic potential of midregional pro-adrenomedullin following decompensation for systolic heart failure: comparison with cardiac natriuretic peptides. Eur J Heart Fail 2017;19:1166-75.
22. Gaynitdinova VV, Avdeev SN. Novel biomarkers of pulmonary hypertension. Kardiologiia 2019;59:84-94.
23. Ter Maaten JM, Kremer D, Demissei BG, et al. Bioadrenomedullin as a marker of congestion in patients with new-onset and worsening heart failure. Eur J Heart Fail 2019;21:732-43.